| DARPP-32 (dopamine- and cAMP-regulated phosphoprotein, PPP1R1B) is a cytosolic, intrinsically disordered protein highly enriched in neostriatal medium spiny neurons (MSNs), where it integrates dopaminergic and glutamatergic signals crucial for basal ganglia function. Its flexible, unstructured nature enables multisite phosphorylation at key residues, Thr34 (PKA site, mediating PP1 inhibition), Thr75 (CDK5 site, inhibiting PKA), Ser102 (CK2 site, enhancing PKA efficacy), and Ser137 (CK1 site, modulating PP2B sensitivity), allowing combinatorial phospho-states that finely tune kinase and phosphatase balance without the need for rigid domains. Phosphorylation at Thr34 by D1R/cAMP/PKA turns DARPP-32 into a potent PP1 inhibitor, amplifying PKA-dependent phosphorylation of targets such as AMPA receptors, CREB, and histone H3, thereby potentiating striatal output, synaptic plasticity, and reward-related behaviors; in contrast, Thr75 phosphorylation by CDK5 inhibits PKA, counteracting dopamine effects, while Ser137 phosphorylation introduces timing-dependent integration of cAMP and Ca²⁺ signals via feedforward loops. This bidirectional, combinatorial regulation underlies MSN pathway excitability, long-term synaptic plasticity, and complex motivated behaviors. DARPP-32 is implicated in addiction (upregulated with psychostimulant use), Parkinson’s disease (D2-dependent dephosphorylation deficits), schizophrenia (Thr75 polymorphism-associated), depression, and frontostriatal cognitive impairment. |
